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Abstract 
Objectives: PainDETECT is a self-report questionnaire that can be used to identify features 
of neuropathic pain. A proportion of patients with knee osteoarthritis score highly on the 
PainDETECT questionnaire. This study aimed to determine whether those with a higher 
„positive neuropathic‟ score on the PainDETECT questionnaire also had greater pain, 
hypersensitivity and reduced function compared to individuals with knee OA with lower 
PainDETECT scores.  
Methods: 130 participants with knee OA completed the PainDETECT, Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) and Pain Quality Assessment Scale 
(PQAS) questionnaires. Quantitative sensory testing was carried out at three sites (both knees 
and elbow) using standard methods. Cold and heat pain thresholds were tested using a Peltier 
thermode and pressure pain thresholds using a digital algometer. Physical function was 
assessed using three timed locomotor function tests.  
Results: 22.3% of participants scored in the „positive neuropathic‟ category with a further 
35.4% in the unclear category. Participants in the „positive neuropathic‟ category reported 
higher levels of pain and more impaired function based on the WOMAC questionnaire 
(p<0.0001). They also exhibited increased levels of hyperalgesia at the knee and upper limb 
sites for all stimulation modalities except heat pain thresholds at the OA knee. They were also 
slower to complete two of the locomotion tasks.  
Discussion: This study identified a specific sub-group of people with knee OA who exhibited 
PainDETECT scores in the „positive neuropathic‟ category. These individuals experienced 
increased levels of pain, widespread, multi-modality hyperalgesia and greater functional 
impairment than the remaining cohort. Identification of OA patients with this pain phenotype 
may permit more targeted and effective pain management.  
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Introduction 
Osteoarthritis (OA) is a common arthritic disorder [1, 2], often associated with pain and local 
tenderness or pressure hyperalgesia around the affected joint(s) [3, 4]. Although knee OA has 
been considered the archetypal model of inflammatory or nociceptive pain [5], it is 
increasingly apparent that people with knee OA may present with different pain phenotypes. 
It is now recognised that some individuals with knee OA exhibit features of neuropathic pain 
[6] and it has been suggested that neuropathic pain in OA may be the result of damage to 
sensory neurons in subcortical bone as a result of the degenerative pathology [7-9]. This 
relates to the concept of neuropathic pain being, “pain arising as a direct consequence of a 
lesion or disease affecting the somatosensory system” [10]. 
One approach to evaluating the presence of neuropathic pain has been to use self-report 
questionnaires such as PainDETECT, Doleur Neuropathic 4 (DN4) and the Leeds 
Assessment of Neuropathic Symptoms and Signs (S-LANSS). These questionnaires 
predominantly evaluate the degree to which the individual reports phenomena such as 
burning pain, shooting or lancinating pain, tactile allodynia and other features that are 
normally associated with neuropathic pain states.  
 The PainDETECT questionnaire uses a combination of visual analogue scale, body diagram 
and Likert-type questions to ask about everyday frequency of symptoms such as „electric 
shocks‟ or „painful light touch‟. A total score is calculated, with subjects scoring ≤12 
classified as „negative neuropathic‟ and those scoring ≥19 as „positive neuropathic‟. The 
group with intermediate scores (13-18) is classified as unclear or possible neuropathic [11].  
A number of studies have evaluated people with knee OA using the PainDETECT 
questionnaire and demonstrated that some individuals score in the „positive neuropathic‟ 
range. The percentage of people with increased PainDETECT scores (≥19) in the „positive 
neuropathic‟ category appears to vary between OA cohorts, ranging from 5.4% to 32% 
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although the majority of studies suggest a percentage at the higher end of this range [6, 7, 12]. 
Similar percentages have also been identified using the DN4 questionnaire (29.4%) [13] and 
the S-LANSS questionnaire (30%) [14].  
Previous research also suggests that increased PainDETECT scores in individuals with knee 
OA are associated with changes in quantitative sensory testing (QST) measures suggestive of 
increased pain sensitivity and with higher scores on the Western Ontario and McMaster 
Universities Arthritis Index (WOMAC) [14, 15]. However, these studies have not clearly 
differentiated between PainDETECT categories in terms of QST measures and functional 
capacity. 
The current study sought to explore the relationship between self-report of neuropathic pain 
(based on PainDETECT scores) and pain report, sensory impairment, multi-modality 
hyperalgesia and impaired physical function in individuals with knee OA.  
The primary aim of the study was to determine if there were differences in measures of pain, 
hyperalgesia, sensation and function between three sub-groups of participants categorised by 
PainDETECT scores („negative neuropathic‟ (≤12), „unclear neuropathic‟ (13-18) and 
„positive neuropathic‟ (≥19).   
Materials and Methods 
Participants 
One hundred and thirty participants with painful knee OA were recruited from the Perth 
community. Participants were assessed for suitability by a Rheumatologist, using the 
American College of Rheumatology (ACR) classification system [16].  People who were 
diagnosed as having knee OA based on the ACR criteria and who reported pain ≥4 /10 were 
included in the study. Exclusion criteria included: history of systemic inflammatory 
conditions; neurological disorders affecting sensory or motor function; recent (<6 months) 
lower limb injury or surgery; or history of other chronic pain disorders (e.g. fibromyalgia).  
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All participants provided written informed consent before participating in the study. Ethical 
approval was provided by Royal Perth Hospital Medical Research Ethics Committee 
(EC2009/100 and REG 13-005) and by Curtin University Human Research Ethics Committee 
(HR26/2010 and 79/2013). 
Study Design and Procedure 
The study used a cross-sectional design, with subjects attending for one test session. 
Participants underwent a washout period equal to five half lives of their analgesic or NSAID 
medication before testing. They were able to use paracetamol (acetaminophen) for analgesia 
if required during this washout period but were asked to refrain from its use for 12 hours 
before testing. All subjects initially completed the WOMAC Osteoarthritis Index for the 
Knee [17], the PainDETECT questionnaire [11] and the Pain Quality Assessment Scale 
(PQAS) [18]. They then completed a series of QST measures and a series of tests of physical 
function.  
Self-Report Questionnaires 
PainDETECT is a validated self-report tool with good internal consistency and high 
sensitivity and specificity that has been used to identify neuropathic pain features in a range 
of conditions [11]. The maximum score is 30 with scores ≥19 being designated as „positive 
neuropathic‟. 
 PQAS was also used to provide data regarding the type of spontaneous pain experienced 
[18]. The questionnaire includes 17 questions about the type of pain plus additional numerical 
rating scales for unpleasantness and surface versus deep pain. Three pain sub-scores are then 
calculated [18]: paroxysmal, surface and deep. The questionnaire has demonstrated good 
reliability and excellent internal consistency for all of the sub-scales [18]. It has been 
suggested that differences between the deep and surface or paroxysmal subscale scores may 
differentiate nociceptive-type and neuropathic-type pain [18]. 
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WOMAC was used to evaluate subjective pain, stiffness and functional limitation . This OA-
specific self-report scale has been widely used to measure pain and disability from knee OA, 
demonstrating good internal validity and test-retest reliability [17]. A higher score denotes 
greater functional limitation. 
Physical Function Tests 
The Aggregated Locomotor Function (ALF) test [19] was used as a measure of observed 
locomotor function. The score was calculated by summing the time (seconds) taken to 
complete 3 locomotor tasks: walk 2-metres to a chair, sit, stand and walk back 2-metres; 8-
metre return walk; ascend / descend 10 stairs. All instructions were standardized, with 
subjects asked to complete each task “as briskly as possible”. The score has good inter-rater 
reliability and is moderately well correlated with both WOMAC and SF-36 function indices, 
and is reported to be responsive to change following intervention over a short time period 
[19]. 
Quantitative Sensory Tests 
All quantitative sensory tests were applied using standardized instructions at standardized 
sites: at the OA knee and the contralateral knee (medial joint line) and at the ipsilateral elbow 
over the extensor carpi radialis brevis (ECRB) muscle [20]. Triplicate measures were 
obtained. Order of testing was randomized between QST modalities and between test sites. 
Pressure Pain Threshold (PPT) was assessed using an electronic digital pressure algometer 
(Somedic AB, Sweden), a device with good test retest reliability [21]. A 1cm² algometer 
probe was applied at 90° to the skin at a rate of 40kPa/sec. Subjects were instructed to press 
the hand-held switch as soon as the sensation of pressure became one of painful pressure 
[22]. Lower PPT values indicate increased sensitivity. 
Cold Detection and Cold Pain Thresholds (CDT & CPT) were measured using a Peltier 
thermode (Medoc, Israel) and standard Method of Limits [23]. The probe was attached to the 
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test site with a Velcro™ strap. The temperature reduced at a rate of 1°C/sec from a baseline 
temperature of 32°C to a minimum of 0°C. Cold detection threshold (CDT) was always 
measured first. Participants were instructed to press the hand-held switch as soon as they 
perceived any cooling change from baseline. For cold pain threshold (CPT), participants were 
instructed to press the switch as soon as the cooling sensation changed to one of painful cold. 
Some subjects failed to indicate cold pain before the thermode reached the minimum 
temperature of 0°C. These participants were assigned a cold pain threshold of 0°C. Higher 
CPT values indicate increased cold pain sensitivity. 
Warm Detection and Heat Pain Thresholds (WDT & HPT) were measured with the Medoc 
Peltier thermode using similar methodology to cold testing (baseline 32°C, 1°C/sec ascending 
ramp), with maximum temperature set at 50°C. Warm detection threshold (WDT) was 
defined as the temperature (°C) at which participants first perceived an increase in warmth 
from baseline, whilst heat pain threshold (HPT) was defined as the temperature (°C) at which 
participants perceived that the heating sensation had become one of painful heat. Some 
subjects failed to indicate heat pain before the thermode reached the maximum temperature 
of 50°C. These participants were assigned a heat pain threshold of 50°C. Lower HPT values 
indicate increased heat pain sensitivity. 
Statistical Analysis 
Data were analyzed using SPSS version 22 (IBM Corp) with Alpha set at p<0.05. 
Participants were divided post hoc into three groups based on PainDETECT score (≤12, 13-
18, ≥19). Data were evaluated to determine if they met the assumption of normality using the 
Shapiro-Wilk test. Those measures that were normally distributed were analysed using one 
way ANOVA with Dunnett t Post Hoc tests using the high PainDETECT group (≥19) as 
control. Data that were not normally distributed were analysed using the non-parametric 
independent samples Kruskal-Wallis test and the Mann-Witney U test. 
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Based on previous research it was predicted that 15-25% of participants would score in the 
„positive neuropathic‟ category on PainDETECT [6, 7, 12]. With an estimated sample size of 
n=20 for the high PainDETECT group, it was calculated that the study would have 80% 
power to detect a between-groups mean difference of 38kPa (SD 57kPa) in PPT, a 5.4˚C (SD 
2.3˚C) difference in CPT and a 7.8 mm (SD 16mm) difference in total WOMAC score [24]. 
These values equate to a 15-20% between group difference [24]. Based on the high 
PainDETECT group constituting 15% of the overall cohort a sample of 130 subjects with 
knee OA was recruited for the study. 
Results 
Subject demographics 
The 130 participants (62 male: 68 female) had a mean age of 66 years (range 50-88 years). 
They reported moderate pain (WOMAC Pain 18.5/50) and functional disability (WOMAC 
function 60.6/250).  
Based on PainDETECT score 29 participants (22.3%) were classified as „positive 
neuropathic‟ (score ≥19), 46 as „unclear neuropathic‟ (35.4%) (Score 13-18) and 55 as 
„negative neuropathic‟ (42.3%) (Score ≤12).  
Participants predominantly used paracetamol/acetaminophen or non-steroidal anti-
inflammatory drugs (NSAIDs) for pain management (Table 1). They reported a number of 
co-morbidities with diabetes and high blood pressure reported by a higher proportion of the 
„positive neuropathic‟ group (Table 1). 
 Self-Report Questionnaires 
There were significant differences between PainDETECT categories for WOMAC pain 
scores (F2,127 =18.23, p<0.0001), function scores (F2,127 =18.30, p<0.0001), stiffness scores 
(F2,127=10.38, p<0.0001) and total scores (F2,127=22.28, p<0.0001). Post hoc tests (Dunnett‟s 
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t) showed significant differences between the „positive neuropathic‟ group and each of the 
other groups for pain, function, stiffness and total score (Figure 1).   
PQAS scores also showed differences between the PainDETECT groups for the paradoxical 
(F2,127=18.66, p<0.0001) and surface (F2,127=43.44, p<0.0001) pain categories but there was 
no significant difference for the deep pain category (F2,127 =2.33, p=0.10). Post hoc tests 
showed significant differences (p<0.0001) between the „positive neuropathic‟ group and each 
of the other PainDETECT groups for paradoxical pain and surface pain (Figure 1). There was 
a significant difference between the „positive neuropathic‟ and „negative neuropathic‟ groups 
(p=0.029) for deep pain but no difference between the „positive neuropathic‟ group and the 
unclear group (p=0.141) (Figure 1). 
Physical Function Tests 
There was a significant difference between PainDETECT groups for the stair climb 
(p=0.001) and walk (p=0.004) components of the ALF, and the total score (p=0.007) but no 
significant difference for the sit-to-stand (p=0.676) component (Figure 1). Comparisons 
between the „positive neuropathic‟ and „negative neuropathic‟ groups followed the same 
pattern (stair p<0.001, walk p=0.002, sit-to-stand p=0.369, total p=0.003). There was also a 
significant difference between the „positive neuropathic‟ group and the unclear group for the 
stair component of the test (p=0.024).  
Quantitative Sensory Tests 
Pain Thresholds 
There were significant differences in pressure pain thresholds at the index knee (F2,127=24.56, 
p<0.0001), contralateral knee (F2,127=27.69, p<0.0001) and ECRB sites F2,127=10.22, 
p<0.0001). Post hoc tests showed significantly (p<0.0001) lower PPTs (sensitized) for the 
„positive neuropathic‟ group relative to the „negative neuropathic‟ group at all test sites but 
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no significant difference between the „positive neuropathic‟ group and the unclear group 
(Figure 2).  
Cold pain thresholds were also significantly different between PainDETECT groups at all 
sites (Kruskal-Wallis Test: index knee p<0.001; contralateral knee p<0.001; ECRB p<0.001). 
CPTs for the „positive neuropathic‟ group were significantly (p<0.001) higher (sensitized) 
than the „negative neuropathic‟ group at all sites but there was no difference between the 
„positive neuropathic‟ group and the unclear group at any site (Figure 2). 
Similarly, there were significant differences in heat pain thresholds at the contralateral knee 
(p=0.004) and the ECRB site (p=0.02) but not at the index knee (p=0.72). HPTs for the 
„positive neuropathic‟ group were significantly lower (sensitized) than the „negative 
neuropathic‟ group at the contralateral knee (p=0.001) and ECRB sites (p=0.007) but not at 
the index knee (p=0.472). There was a significant difference between the „positive 
neuropathic‟ group and the unclear group at the contralateral knee (p=0.041) but no 
difference at the other sites (Index knee p=0.466; ECRB p=0.212) (Figure 2). 
Sensory Thresholds 
Cold detection thresholds were not significantly different at any site (Index knee p=0.935; 
Contralateral knee p=0.455; ECRB p=0.118) (Figure 3). There was a significant difference in 
warmth detection thresholds at the contralateral knee (p=0.005) but not at the other sites 
(index knee p=0.069; ECRB p=0.453) (Figure 3). At the index knee (p=0.033) and the 
contralateral knee (p=0.018) there was a significant difference between the „positive 
neuropathic‟ group and the „negative neuropathic‟ group indicating some degree of sensory 
impairment but there was no difference between the „positive neuropathic‟ group and the 
unclear group at any site. 
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Discussion 
This study investigated levels of pain, hyperalgesia and physical function in participants with 
knee OA, grouped according to PainDETECT score. Those scoring in the „positive 
neuropathic‟ category reported the greatest pain and disability, and demonstrated widespread 
hyperalgesia and greater functional limitations. 
Participants with knee OA in this study demonstrated a range of PainDETECT scores from 0 
to 30 (of a maximum score 30), reflecting very heterogeneous pain experiences. 22.3% of the 
participants scored in the „positive neuropathic‟ category, suggesting that they may be 
experiencing features of neuropathic pain. In previous studies the percentage of participants 
scoring in the „positive neuropathic‟ pain category has ranged from 5.4% to 32% [6, 7, 12]. 
The findings from this study are therefore a little less than some previous studies but 
nevertheless within the previously published range.  
When tested across a range of other self-report measures, participants in the „positive 
neuropathic‟ pain category reported increased pain and decreased function relative to the 
remaining patient cohort. WOMAC pain, stiffness and function sub-scores were elevated for 
this group. There are no previous studies that have evaluated minimum clinically important 
differences (MCID) between patient cohorts, but the 32% reduction in WOMAC total score 
between the „positive neuropathic‟ group and the intermediate group is considerably larger 
than the 16% MCID for reduction in total WOMAC score following drug treatments [25].  
The „positive neuropathic‟ pain group also reported significantly higher scores than the 
remaining cohort for the surface and paradoxical pain quality subscales of PQAS, both of 
which are thought to reflect features of neuropathic pain [18]. It therefore appears that this 
group experiences not just increased pain severity but also distinctive pain qualities that are 
often associated with neuropathic pain. 
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In addition to WOMAC self-report of reduced functional capacity, participants in the 
„positive neuropathic‟ group were slower to complete physical tasks. They exhibited slower 
times for the stair climb and walk components of the ALF test and had significantly increased 
total times. This further emphasizes that they were experiencing greater functional limitation 
associated with their pain. 
Participants in the „positive neuropathic‟ category also exhibited widespread, multi-modality 
hyperalgesia or increased pain sensitivity relative to those in the „negative neuropathic‟ 
category. In addition to increased pain sensitivity at the OA knee, these participants were also 
more sensitive to measures of pressure pain threshold, cold pain threshold and heat pain 
threshold at the distant ECRB test site in the upper limb. Differences in PPT between groups 
exceeded the reported MCID of 114kPa [26] at both knees but not at the ECRB site. 
Interestingly, there was no significant difference in heat pain threshold at the index knee. This 
was a somewhat surprising finding given the clear differences that were present at the other 
test sites and the other test modalities. In a recent publication we have demonstrated that a 
sub-group of patients with increased cold pain thresholds also present with widespread multi-
modality hyperalgesia and increased PainDETECT scores [27] 
However, a „positive neuropathic‟ score on the PainDETECT questionnaire alone is not 
diagnostic of pain that is neuropathic in origin. Treede et al. have proposed a grading system 
with categories of possible, probable and definite neuropathic pain [10]. Inclusion in the 
probable neuropathic pain category requires the presence of a measured sensory deficit in an 
area clearly related to the area of neuropathic pain report. Definite neuropathic pain also 
requires the existence of imaging or other findings showing a clear causative neuropathology 
[10].  
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The current study‟s findings suggest that while some individuals with knee OA may score 
highly on the PainDETECT questionnaire there is limited evidence of associated sensory 
impairment. There were no marked changes in sensory thresholds for cold although there 
were differences in warmth detection thresholds suggesting some impaired sensation in the 
„positive neuropathic‟ grouping. However these findings are inconclusive. It should be noted 
that sensory testing was only carried out at one knee location (medial joint line). Since the 
area around the knee is innervated by multiple peripheral nerves [28], a single test site is 
unlikely to adequately evaluate sensory deficits. It is also important to acknowledge a 
limitation of the study in that comprehensive testing of light touch, pinprick and vibration 
sensations was not carried out. Further research is therefore warranted to explore more 
closely the relationship between pain and neurological deficits in patients with knee 
osteoarthritis. In addition to sensory deficits the concurrent presence of proprioceptive 
deficits might also be explored. Is it notable that deficits in proprioceptive function have 
previously been identified in patients with knee OA [29]. Future studies would also benefit 
from including data from a control cohort to account for normal variations in sensation 
amongst an older cohort. 
It may also be the case that an increased PainDETECT score in association with widespread 
multimodality hyperalgesia may simply reflect a centrally augmented pain state [14, 15] 
rather than the presence of neuropathic pain. This may reflect enhanced central sensitization 
and possibly also impaired pain modulation [4]. Further research is required to evaluate the 
development of widespread pain sensitivity and impaired pain modulation to determine if 
these findings are also present in individuals who do not present with increased PainDETECT 
scores.  
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Although this study evaluated a relatively small cohort, the findings clearly suggest that 
scores on the PainDETECT questionnaire may be a useful indicator of those with a more 
severe pain state. These findings add further support to the concept that people with knee OA 
present with different pain phenotypes and so may have significantly different experiences of 
osteoarthritic pain [9]. In particular, they suggest that a sub-cohort of patients with knee OA 
experience more severe „neuropathic-type‟ pain that has a greater impact on physical function 
than other individuals with the same condition. A previous study showed that patients with 
ongoing pain more than one year post joint replacement surgery showed that this group had 
higher PainDETECT scores and more functional impairment than patients with minimal pain 
following surgery [30]. This suggests that a standardized approach to pain management might 
result in some patients with knee OA receiving inadequate treatment and highlights the need 
for further research to develop clear criteria to diagnose neuropathic pain in knee OA and to 
optimize the management of pain in this patient group. In particular, it may be appropriate to 
consider the use of neuropathic pain medications in a sub-group of people with knee OA. 
Further research is warranted to evaluate this grouping in larger patient cohorts and clinical 
trials evaluating the efficacy of drugs used to manage neuropathic pain in this sub-group of 
OA sufferers. 
Conclusion 
Individuals with knee OA may report markedly different scores on the PainDETECT 
questionnaire. Those who score highly on the questionnaire tend to report increased pain, 
different pain qualities, more functional impairment and more widespread, multimodality 
hyperalgesia and pain sensitivity than other people with a diagnosis of knee OA. Further 
research is needed to determine whether these individuals can be clearly classified as having 
neuropathic pain if they would benefit from more targeted pain management. 
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Figure Legends 
Figure 1. Comparison between the „negative neuropathic‟ (≤12), unclear (13-18) and „positive 
neuropathic‟ (19+) PainDETECT categories for scores obtained in the subcategories of the WOMAC 
questionnaire (Panel a), the PQAS questionnaire (Panel b) and the ALF test (Panel c) (* p<0.05, ** 
p<0.001, *** p<0.0001). 
Figure 2. Comparison between the „negative neuropathic‟ (≤12), unclear (13-18) and „positive 
neuropathic‟ (19+) PainDETECT categories for pressure pain thresholds (Panel a), cold pain 
thresholds (Panel b) and heat pain thresholds (Panel c) at each of three test sites (* p<0.05, ** 
p<0.001, *** p<0.0001). 
Figure 3. Comparison between the „negative neuropathic‟ (≤12), unclear (13-18) and „positive 
neuropathic‟ (19+) PainDETECT categories for cold sensation thresholds (Panel a) and warm 
detection thresholds (Panel b) at each of three test sites (* p<0.05, ** p<0.001, *** p<0.0001). 
 
  
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited. This is an open-access article distributed under 
the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided 
it is properly cited. The work cannot be changed in any way or used commercially.



















      Paracetamol/ 
acetaminophe
n 22 20 15 57 43.8 p=0.671 
NSAIDs 18 22 16 56 43.1 p=0.116 
Tramadol 1 1 3 5 3.8 p=0.135 
Co-morbidities 
     Diabetes 8 6 10 24 18.5 p=0.076 
BP 9 10 13 32 24.6 p=0.020 
LBP 21 21 18 60 46.2 p=0.155 
Neck pain 8 6 7 21 16.2 p=0.470 
Migraines 6 3 4 13 10.0 p=0.614 
Depression 7 9 8 24 18.5 p=0.271 
IBS 2 4 3 9 6.9 p=0.442 
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